Search Results

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral

GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery committed to leveraging his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical GPCR About Cam Sinh Lu Cam Sinh Lu is a PhD student at Monash Institute of Pharmaceutical Sciences, Monash